These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819 [TBL] [Abstract][Full Text] [Related]
5. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Lee SH; Walshe M; Oh EH; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Greener T; Weizman AV; Silverberg MS; Ye BD Inflamm Bowel Dis; 2021 Aug; 27(9):1452-1461. PubMed ID: 33269403 [TBL] [Abstract][Full Text] [Related]
6. Case Report: Proteinase 3 Antineutrophil Cytoplasmic Antibody-Associated Ulcerative Colitis Presenting as Recurrent Intestinal Pseudo-Obstruction in a Teenage Patient With Yang CW; Kao YC; Lin PC; Chien HY; Lin SC; Lee YH; Huang YL; Fang SB Front Pediatr; 2022; 10():822491. PubMed ID: 35281249 [TBL] [Abstract][Full Text] [Related]
7. Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring. Kumar P; Vuyyuru SK; Das P; Kante B; Ranjan MK; Thomas DM; Mundhra S; Sahu P; Venigalla PM; Jain S; Goyal S; Golla R; Virmani S; Singh MK; Sachdeva K; Sharma R; Dash NR; Makharia G; Kedia S; Ahuja V Intest Res; 2023 Oct; 21(4):460-470. PubMed ID: 36926698 [TBL] [Abstract][Full Text] [Related]
8. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease. Horn MP; Peter AM; Righini Grunder F; Leichtle AB; Spalinger J; Schibli S; Sokollik C PLoS One; 2018; 13(12):e0208974. PubMed ID: 30557305 [TBL] [Abstract][Full Text] [Related]
9. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Xu Y; Xu F; Li W; Li M; Dong S; Zhang Y; Norman GL; Zhao Q; Liu L Scand J Gastroenterol; 2020 Jul; 55(7):806-813. PubMed ID: 32568566 [No Abstract] [Full Text] [Related]
10. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138 [TBL] [Abstract][Full Text] [Related]
11. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397 [TBL] [Abstract][Full Text] [Related]
12. Clinical Validity of Anti-Proteinase 3 Antibodies in Patients with Inflammatory Bowel Disease: A Short Meta-Analysis. Andalucía C; Martínez-Prat L; Bentow C; Aure MA; Horn MP; Mahler M Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132266 [TBL] [Abstract][Full Text] [Related]
13. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Arias-Loste MT; Bonilla G; Moraleja I; Mahler M; Mieses MA; Castro B; Rivero M; Crespo J; López-Hoyos M Clin Rev Allergy Immunol; 2013 Aug; 45(1):109-16. PubMed ID: 23345025 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161 [TBL] [Abstract][Full Text] [Related]
16. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817 [TBL] [Abstract][Full Text] [Related]